ICER Names Leigh Purvis to Governance Board and Dr. Mark McClellan to Advisory Board
Leigh Purvis, MPA, Director of Health Care Costs and Access in AARP's Public Policy Institute, has been elected to the [...]
[Podcast] A Prescription for Fair Drug Pricing
ICER has announced the launch of a new podcast series entitled “A Prescription for Fair Drug Pricing.” In this series [...]
Incentivizing Novel Antibiotic Development–Netflix-Style
Drug makers have been increasingly disincentivized from developing novel antibiotics due to higher development costs and antibiotic stewardship programs, resulting [...]
HTA and Affordability for Innovative Therapies in Germany
A major challenge facing both HTA authorities and manufacturers is integrating new and innovative treatments into the healthcare system. A [...]
Bringing Value-Based Insurance Design to Oncology
Although the oncology field has been increasingly adopting value-based insurance designs, much work yet remains. For decades, the traditional dogma [...]
JMCP’s Call to Action in Addressing Racial Disparities in Medication Use
In a recently published article, the editorial team at 'Journal of Managed Care + Specialty Pharmacy' (JMCP) raised the question [...]
Takeda Partners With Seqster on Patient-centric Data
Seqster, a San Diego-based health technology firm, developed a platform to securely collate and store patient data such as electronic [...]
Milestones in managed care pharmacy
There have been major achievements in managed care pharmacy’s short 50-year history. Significant milestones include establishment of the pharmacy benefit [...]
FDA and Industry Set Priorities Through Prescription Drug User Fee Act (PDUFA) Reauthorization
The FDA first began the Prescription Drug User Fee Act (PDUFA) reauthorization process in July. Now the agency has released [...]
FDA Decision Alerts for AYVAKIT™ (avapritinib) and IBRANCE (palbociclib)
Blueprint Medicines Corporation’s AYVAKIT (avapritinib) was approved for adult patients with a specific type of unresectable or metastatic gastrointestinal stromal [...]
Generating Insights from RWD: Opportunities for Small and Mid-sized Biopharma
Optum possesses a robust range of real-world data (RWD) assets that afford small and mid-sized biopharma the unique opportunity to [...]
[Podcast] Where Value-Based Payments and Behavioral Health Intersect
Tune in to this healthcare podcast featuring Don Fowls, MD, president of Don Fowls and Associates, and past president of [...]
[White Paper] Integrated Scientific Advice and Multiple Stakeholder Engagements
Ensuring the best chance of success for new technologies through development of evidence generation plans requires multi-stakeholder involvement with patients, [...]
NICE Talking to You: The Value of Early Scientific Advice
Starting in 2009, NICE became a pioneer among health technology assessment (HTA) agencies by offering the opportunity for early scientific [...]
The Disturbing Dearth of Evidence for Supportive Oncology
Despite historical reliance on evidence generated from randomized controlled trials (RCTs), there has been a surge in the number of [...]
ICER Launches New Podcast: A Prescription for Fair Drug Pricing
America’s got a fever. And the only prescription? More cowbell—and fair drug pricing. To that end, ICER announced the launch [...]
[White Paper] Health Technology Assessment During the COVID-19 Pandemic
The global COVID-19 pandemic currently permeates every aspect of daily life with long-lasting consequences for all sectors, including pharma and [...]
COVID-19 Vaccine Will Come At No Cost to Medicare Beneficiaries
Once approved, the Trump administration will cover COVID-19 vaccinations at no cost to Medicare beneficiaries. On Wednesday, CMS released an [...]
Evidence Forum Announces Fall Issue
Evidera’s biannual publication, Evidence Forum, explores the pressing scientific, strategic, and operational challenges of the current healthcare environment. The fall [...]
New Rule Requires Payers To Post Negotiated Rates, Cost-sharing Data
The Trump administration announced today that it has finalized a rule requiring private insurers to provide members with upfront prices negotiated [...]
AMI’s Specialty Pharmacy Database Enjoys Growing Accreditation Status
AMI’s Specialty Pharmacy Database recently gained accreditation status from four agencies: URAC, Accreditation Commission for Health Care (ACHC), The Center [...]
Bureaucrats May Stop Life-saving Meds from Reaching Canada
If Canadian bureaucrats on the Patent Medicine Prices Review Board (PMPRB) get their way, innovative new drugs and vaccines may not come [...]
How Can Payers Advance Patient-reported Measures in Oncology?
A newly published study explored patient-reported performance measures in oncology, the barriers to implementation, and actionable recommendations for public and [...]
Achieving Accurate Estimates of Shared Savings from Value-based Healthcare
This article is part of a series focused on calculating shared savings from value-based health care improvement solutions. There is [...]
[Podcast] Bruno Villetelle on Real World Data’s Role in Bringing Medication to Market
In this episode of Real World Talk, join host Emily Di Capua as she discusses the ways in which RWD [...]